Bionano Genomics (BNGO)
(Real Time Quote from BATS)
$0.41 USD
0.00 (1.11%)
Updated Sep 23, 2024 01:00 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Bionano Genomics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 36 | 28 | 18 | 9 | 10 |
Cost Of Goods | 27 | 22 | 14 | 6 | 7 |
Gross Profit | 10 | 6 | 4 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 225 | 138 | 81 | 41 | 29 |
Income After Depreciation & Amortization | -215 | -132 | -77 | -39 | -26 |
Non-Operating Income | -12 | 1 | 0 | 0 | -2 |
Interest Expense | 5 | 0 | 1 | 3 | 2 |
Pretax Income | -232 | -131 | -78 | -41 | -30 |
Income Taxes | 0 | 2 | -6 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -232 | -133 | -72 | -41 | -30 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -232 | -133 | -72 | -41 | -30 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -125 | -121 | -73 | -37 | -25 |
Depreciation & Amortization (Cash Flow) | 91 | 10 | 4 | 1 | 1 |
Income After Depreciation & Amortization | -215 | -132 | -77 | -39 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 34.15 | 28.92 | 27.68 | 10.43 | 1.50 |
Diluted EPS Before Non-Recurring Items | -5.07 | -4.60 | -2.60 | -3.90 | -19.00 |
Diluted Net EPS (GAAP) | -6.81 | -4.60 | -2.60 | -3.90 | -19.90 |
Fiscal Year end for Bionano Genomics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 7.77 | 8.77 | 10.72 | 9.32 | 8.66 |
Cost Of Goods | 5.19 | 5.95 | 8.28 | 6.57 | 6.35 |
Gross Profit | 2.59 | 2.82 | 2.44 | 2.75 | 2.31 |
SG&A, R&D, and Dept/Amort Expenses | 19.60 | 33.95 | 27.39 | 115.97 | 41.55 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.01 | -31.13 | -24.95 | -113.22 | -39.24 |
Non-Operating Income | 0.82 | -0.19 | -14.08 | 0.76 | 0.43 |
Interest Expense | 0.00 | 0.12 | 4.90 | 0.07 | 0.07 |
Pretax Income | -16.20 | -31.44 | -43.93 | -112.53 | -38.88 |
Income Taxes | 0.03 | -0.02 | -0.04 | 0.04 | 0.03 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.22 | -31.42 | -43.89 | -112.57 | -38.91 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.22 | -31.42 | -43.89 | -112.57 | -38.91 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 67.58 | 52.74 | 45.72 | 35.00 | 31.50 |
Diluted EPS Before Non-Recurring Items | -0.24 | -0.60 | -0.96 | -1.48 | -1.24 |
Diluted Net EPS (GAAP) | -0.24 | -0.60 | -1.15 | -3.22 | -1.24 |